Cost-Effectiveness Analysis Of Daclatasvir/Sofosbuvir (DCV/SOF) For The Treatment Of HCV Patients Who Failed After First Line Treatment With Second Generation Of Daa In Italy
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.2305
https://www.valueinhealthjournal.com/article/S1098-3015(17)32639-6/fulltext
Title :
Cost-Effectiveness Analysis Of Daclatasvir/Sofosbuvir (DCV/SOF) For The Treatment Of HCV Patients Who Failed After First Line Treatment With Second Generation Of Daa In Italy
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)32639-6&doi=10.1016/j.jval.2017.08.2305
First page :
A787
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2122